Growth stocks have been all the rage in the post-pandemic era, and there’s a good chance that they could continue spearheading the market’s gains. The current economic fundamentals look solid, and some believe it is almost too good to be true.

And recent news from Lululemon offers us reason to be optimistic. The company reported a successful holiday season, allowing it to raise its fourth-quarter 2024 revenue, earnings per share, and gross margin guidance. The new forecast implies 11% to 12% revenue growth year over year.

Nevertheless, growth stocks outperformed value stocks in 2024, and investors anticipate that trend will continue as the Federal Reserve cuts interest rates. Here are 10 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years:

Biote: Revolutionizing Hormone Optimization Biote (NYSE: BTMD) represents an innovative play in the growing hormone optimization market.

The "Trump trade" that primarily lifted small and mid-cap stocks post-election has started to fizzle this January. Why? Investors are worried the Federal Reserve won't cut interest rates much this year,